When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Replimune Group, Inc. has lost nearly all its share price gains since mid-October 2020 when it presented encouraging data on two of its oncolytic immunotherapy assets.
A news vacuum, a secondary, and a tepid response to an early-June 2021 update to its programs are to blame.
With the management team responsible for the only FDA-approved HSV-1 therapy and plenty of catalysts upcoming in 1Q22, Replimune merited a deeper dive.
A full investment analysis follows in the paragraphs below.